An impact from DMC-CHC NPs on on- and post-target resistance of CDDP was examined. (A) The effects of DMC-CHC NPs on on-target resistance of cisplatin was determined. DMC-CHC NPs significantly decreased cisplatin-induced TP and PI3k/Akt/ERCC1 signaling in A549 cell. A549 cells were exposed to various concentrations of DMC-CHC NPs (7.5 µg/mL, 15 µg/mL, and 30 µg/mL) and cisplatin for 48 h. (B) The effects of DMC-CHC NPs (7.5 µg/mL, 15 µg/mL, and 30 µg/mL) on post-target resistance of cisplatin was examined. The protein expression of bax, and cytochrome c in A549 cells were determined using Western blotting analysis. The results represent the mean ± SD of three independent experiments. * Indicates the values significantly different from the control. (* p < 0.05; ** p < 0.01).